Details for Patent: 9,616,061

Which drugs does patent 9,616,061 protect, and when does it expire?

Patent 9,616,061 protects CAPLYTA and is included in one NDA.

This patent has twenty-one patent family members in nine countries.

Summary for Patent: 9,616,061

Title:	Methods and compositions for sleep disorders and other disorders
Abstract:	Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations.
Inventor(s):	Sharon Mates, Allen Fienberg, Lawrence Wennogle
Assignee:	Intra Cellular Therapies Inc
Application Number:	US14/885,813
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,616,061
Patent Claim Types: see list of patent claims	Composition; Compound; Dosage form;

Drugs Protected by US Patent 9,616,061

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Intra-cellular	CAPLYTA	lumateperone tosylate	CAPSULE;ORAL	209500-002	Apr 22, 2022		RX	Yes	No	9,616,061		Y
Intra-cellular	CAPLYTA	lumateperone tosylate	CAPSULE;ORAL	209500-003	Apr 22, 2022		RX	Yes	No	9,616,061		Y
Intra-cellular	CAPLYTA	lumateperone tosylate	CAPSULE;ORAL	209500-001	Dec 20, 2019		RX	Yes	Yes	9,616,061		Y

International Family Members for US Patent 9,616,061

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2009251816
Australia	2015218433
Canada	2725342